Open AccessEarly virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda
Author(s) -
Padmini Srikantiah,
Mariam Walusimbi,
Harriet K. Kayanja,
Harriet MayanjaKizza,
Roy D. Mugerwa,
Royce Lin,
Edwin D. Charlebois,
W. Henry Boom,
Christopher C. Whalen,
Diane V. Havlir
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32823ecf6e
Subject(s) - lamivudine , abacavir , zidovudine , medicine , regimen , tuberculosis , population , virology , reverse transcriptase inhibitor , immunology , human immunodeficiency virus (hiv) , sida , viral disease , virus , pathology , hepatitis b virus , environmental health
Triple nucleoside reverse transcriptase inhibitors are recommended as an alternative regimen for HIV-infected patients undergoing tuberculosis treatment in resource-limited settings. Few data exist on the efficacy of such regimens in tuberculosis patients. In 34 tuberculosis/HIV-co-infected patients treated with zidovudine/lamivudine/abacavir, 76% achieved HIV RNA less than 50 copies/ml at 24 weeks. No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population.